NEUROSCIENCE, NEUROPHARMACOLOGY AND EXERCISE SCIENCE
Dr Jacob Thorstensen,
Neuroscientist & Assistant Professor,
Faculty of Health Sciences & Medicine
Bond University, Queensland, Australia &
Honorary Research Fellow
The School of Biomedical Sciences,
The University of Queensland
Queensland, Australia
RESEARCHER PROFILE
Filmed in the Gold Coast, Australia | November 2025
Dr Jacob Thorstensen is an early-career Assistant Professor in Neuroscience and Physiology in the Faculty of Health Sciences & Medicine at Bond University. He is also an honorary research fellow in The School of Biomedical Sciences at The University of Queensland.
Dr Thorstensen graduated first-class honours in exercise science, completed a PhD in neurophysiology at Griffith University, and completed a post-doctoral research fellowship in neurology at The University of Queensland.
His research uses non-invasive neurostimulation techniques to study how the brain and spinal cord control muscles in human subjects.
His findings have been published in several discipline-leading scientific journals including The Journal of Physiology, Journal of Neurophysiology and Neuropharmacology and disseminated at large, international scientific meetings.
His work has unveiled several new neuroscientific mechanisms which have future applications for movement disorders. Recent recognitions include being on the Forbes 30 Under 30 list for the Healthcare & Science Category (2024) and being selected as a Career Achievement Award finalist in the 7NEWS QLD Young Achiever Awards (2025).
Dr Thorstensen sits on the editorial boards for The Journal of Physiology and Journal of Applied Physiology.
He is a part of the executive committee for the Australasian Brain Stimulation Society, and the early career researcher and education committees for the International Society of Electrophysiology and Kinesiology.
He is also part of a team that has recently been funded through a Multiple Sclerosis Australia Incubator Grant for a neurostimulation project.
Source: Supplied
https://orcid.org/0000-0002-6821-1547
-
Next Generation Condom Contraception, Dr Simon Cook
Dr. Simon Cook, Co-Founder and Executive Director of Operations at Eudaemon Technologies, has had a diverse and impactful career journey. Beginning with a background in biotechnology from the University of Wollongong, his focus on bacterial pathogenesis during his PhD led him to study Group A Strep and the streptokinase protein.
Subsequently, Dr. Cook ventured into a unique project funded by the Bill and Melinda Gates Foundation, where he became involved in the development of a next-generation condom to address existing issues such as feel, odour, and taste.
-
Systems genetics to determine risk of developing diabetes complications
Professor Morahan invented the term “Systems Genetics” for the science field that examines how genetic variants can affect whole networks of genes and whole systems; there are now several laboratories and institutes of systems genetics around the world. He also developed the next-generation genetic resource, The Gene Mine, the most powerful of its type in the world, used globally in rapid mapping and identification of genes. Collaborators nationally and internationally have tested The Gene Mine for traits and diseases in which they specialise.
-
Oral administration of insulin for Type 1 Diabetes
Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.
People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.
Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.
